Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Got $1,000? Here Are 2 Unstoppable Dividend Stocks to Buy

By Kody Kester - Sep 19, 2021 at 7:21AM

Key Points

  • Safe yields have become hard to find with the market near all-time highs, but they are out there.
  • Johnson & Johnson is a top-notch name, and its 2.6% yield is arguably the safest in healthcare.
  • Philip Morris International's market-crushing 4.9% yield is secure as the company transitions to a smoke-free future.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Dependable and rationally valued dividend stocks are an income investor's dream.

Aside from the COVID-19-induced bear market in March 2020, the past few years have been difficult for income investors. The S&P 500's average yield has been less than 2% in 44 of the past 48 months, which can make it more challenging to find companies whose payouts are both attractive and sustainable.

But even in a market consistently reaching record highs, there do exist sanely priced stocks offering safe dividend yields that are double to nearly quadruple the S&P 500's current 1.3%.

Johnson & Johnson ( JNJ 2.23% ) and Philip Morris International ( PM 2.25% ) are two such reliable dividend payers.

Person being examined by doctor.

Image source: Getty Images.

A diversified titan of healthcare

At $435 billion (by market capitalization), healthcare titan Johnson & Johnson is a favorite of many dividend investors for several reasons.

First, its business is well-balanced. The pharmaceutical segment is led by immunology drugs such as Stelara and Tremfya, and cancer drugs such as Darzalex and Imbruvica (which is co-owned by Johnson & Johnson and AbbVie). These blockbuster drugs are central to Johnson & Johnson's pharmaceutical segment, which made up 54.3% of the company's total first-half sales of $45.63 billion. 

Another third of Johnson & Johnson's business is made up of the medical devices segment (29.7% of first-half revenue), including that treat cardiovascular conditions, orthopedic issues (i.e., knee and hip replacements), and other conditions that require surgical intervention. The remaining portion (15.9% of first-half sales) consists of its well-known consumer and household brands, such as Neutrogena, Zyrtec, and Band-Aid.

Johnson & Johnson's diversified business mix helped the company's revenue to edge slightly higher in 2020 despite COVID headwinds in the medical devices segment due to delayed elective procedures. And now that this division has fully recovered to pre-COVID levels, the company's revenue growth is set to accelerate compared with last year. Management forecasts total revenue growth of 10.5% to 11.5%, from $82.6 billion in 2020 to $91.3 billion to $92.1 billion in 2021 -- and that's excluding the revenue the company's COVID vaccine is expected to produce this year.

Johnson & Johnson anticipates that its adjusted diluted earnings per share (EPS) will surge to $9.60 to $9.70 this year, up 19.6% to 20.8% year-over-year from the $8.04 it generated in 2020. Even compared with 2019's adjusted diluted EPS base of $8.68, this is still double-digit growth from pre-pandemic levels.

Based on the $4.19 in dividends per share that Johnson & Johnson will pay to shareholders this year, the company's dividend payout ratio will be in the low- to mid-40% range. And Johnson & Johnson has a flawless triple-A credit rating from S&P Global, which is what leads me to believe that its 2.6% dividend yield is the safest in all of healthcare.

These are all key reasons why Johnson & Johnson's 59-year dividend increase streak, which puts it in the rarified ranks of the Dividend Kings, is likely to continue in the years ahead. And conservative income investors can purchase shares of this healthcare stalwart for about 17 times this year's EPS estimates -- a discount given Johnson & Johnson's status as one of the steadiest businesses in the world. A $1,000 investment in Johnson & Johnson could purchase six shares based on the current price of about $165.

A tobacco giant on a mission

Another dividend stock worth considering today is $160 billion tobacco company Philip Morris International. Since being spun off from Altria Group in 2008, Philip Morris International has raised its dividend each year. And while Philip Morris remains synonymous with tobacco for some, the company is actually continuing to execute on its stated goal to "deliver a smoke-free future."

The company's smoke-free, heat-not-burn IQOS product has managed to garner tens of millions of users around the world since its initial launch in Japan and Italy in November 2014. This year alone, its IQOS user base has risen from 17.6 million to 20.1 million as of the second quarter; heated tobacco unit (HTU) volumes, including IQOS, surged 30.1% year over year, from 35.4 billion in the first half of last year to 46.1 billion this year. Meanwhile, cigarette volumes fell 2.2% year over year, from 308.4 billion cigarettes in the first half of last year to 301.7 billion this year.

The gangbusters growth in HTUs helped to propel Philip Morris International's total volume 1.1% higher in the first half of this year compared with the year-ago period. In turn, its net revenue advanced 10% year over year, from $13.80 billion in the first half of last year to $15.18 billion this year.

The increased sales of more profitable, smoke-free products -- from 22.9% of first-half sales last year to 28.5% in the first half of this year -- caused Philip Morris International's adjusted operating income margin to expand 450 basis points, from 40.5% last year to 45% this year.

The strong first-half performance led management to forecast $5.97 to $6.07 in adjusted diluted EPS for this year. This represents 15.5% to 17.4% year-over-year growth compared to the $5.17 in adjusted diluted EPS that was produced last year.

This strong outlook explains why the company recently increased its dividend by 4.2%, which is a solid growth rate considering Philip Morris International's current 4.9% yield. And investors can be confident that this yield is safe, based on a payout ratio in the high-70% to low-80% range for this year.

Finally, Philip Morris International appears to be offering safe, ultra-high yield at a reasonable price. This is supported by the fact that it is trading at approximately 17 times this year's EPS forecast, which is more than fair considering that analysts are predicting 12.6% annual earnings growth over the next five years. A $1,000 investment in Philip Morris International could buy nearly 10 shares of the stock at its current price of $103.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$162.94 (2.23%) $3.56
Philip Morris International Inc. Stock Quote
Philip Morris International Inc.
PM
$91.39 (2.25%) $2.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.